MX346973B - Anticuerpos especificos de tumores y usos para los mismos. - Google Patents
Anticuerpos especificos de tumores y usos para los mismos.Info
- Publication number
- MX346973B MX346973B MX2013003825A MX2013003825A MX346973B MX 346973 B MX346973 B MX 346973B MX 2013003825 A MX2013003825 A MX 2013003825A MX 2013003825 A MX2013003825 A MX 2013003825A MX 346973 B MX346973 B MX 346973B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- same
- specific antibodies
- tumor specific
- uses therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
La presente invención se refiere a los anticuerpos aislados y los fragmentos y derivados de los mismos, los cuales se enlazan a los antígenos tumorales. También se proporcionan las composiciones y los agentes de distribución que incluyen los anticuerpos descritos y los fragmentos y derivados de los mismos; las células que producen los mismos; los métodos para producir los mismos; los métodos para utilizar los mismos para detectar, dirigirse a y/o tratar tumores y/o células metatásticas derivadas de los mismos y/o las células de la línea tumoral; y los métodos para predecir la recurrencia del cáncer en un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/924,952 US8518405B2 (en) | 2009-10-08 | 2010-10-08 | Tumor specific antibodies and uses therefor |
PCT/US2011/037972 WO2012047317A2 (en) | 2010-10-08 | 2011-05-25 | Tumor specific antibodies and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013003825A MX2013003825A (es) | 2013-09-02 |
MX346973B true MX346973B (es) | 2017-04-07 |
Family
ID=44062214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013003825A MX346973B (es) | 2010-10-08 | 2011-05-25 | Anticuerpos especificos de tumores y usos para los mismos. |
Country Status (14)
Country | Link |
---|---|
US (5) | US8518405B2 (es) |
EP (1) | EP2624866B1 (es) |
JP (2) | JP5886299B2 (es) |
KR (1) | KR101883280B1 (es) |
CN (1) | CN103492417B (es) |
AU (1) | AU2011312830B2 (es) |
BR (1) | BR112013008480A2 (es) |
CA (1) | CA2813814C (es) |
DK (1) | DK2624866T3 (es) |
ES (1) | ES2927050T3 (es) |
IL (1) | IL225545A0 (es) |
MX (1) | MX346973B (es) |
RU (1) | RU2595403C2 (es) |
WO (1) | WO2012047317A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
WO2014047278A1 (en) * | 2012-09-20 | 2014-03-27 | Viracor-Ibt Laboratories | A method for determination of cellular immune response to therapeutic vaccines |
US9416395B2 (en) * | 2013-03-15 | 2016-08-16 | City Of Hope | Methods, compositions, and kits for detection of aspergillosis |
US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
WO2017120525A1 (en) * | 2016-01-08 | 2017-07-13 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, t cells comprising the same and methods of using the same |
WO2016090434A1 (en) * | 2014-12-12 | 2016-06-16 | Commonwealth Scientific And Industrial Research Organisation | Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist |
US20180246104A1 (en) * | 2015-08-18 | 2018-08-30 | Agency For Science, Technology And Research | Method for detecting circulating tumor cells and uses thereof |
JP6861418B2 (ja) * | 2015-09-02 | 2021-04-28 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | ヒトt細胞免疫グロブリン及びitimドメイン(tigit)に特異的な抗体 |
SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
AU2017346940B2 (en) * | 2016-10-21 | 2018-08-23 | Zelira Therapeutics Operations Pty Ltd | Prognostic method and kits useful in said method |
IL268058B2 (en) | 2017-01-20 | 2023-09-01 | Magenta Therapeutics Inc | Compositions and methods for depleting cd137 plus cells |
EP3604334A4 (en) * | 2017-03-21 | 2021-03-31 | Peptron, Inc. | ANTIBODIES BINDING SPECIFICALLY TO MUC1 AND ITS USE |
CN110998327A (zh) * | 2017-05-12 | 2020-04-10 | 温口特 | 胆管细胞中使用甲硫氨酰-tRNA合成酶诊断胆管癌的方法 |
CN107118276B (zh) * | 2017-06-23 | 2020-12-04 | 苏州博聚华生物医药科技有限公司 | 一种靶向人肿瘤干细胞的单克隆抗体及其应用 |
RU2670656C9 (ru) * | 2017-08-30 | 2018-12-12 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования роста опухоли в эксперименте |
WO2019129892A1 (en) * | 2017-12-29 | 2019-07-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | T cell receptors for tumor specific proteasome splice variants and uses thereof |
WO2019140100A1 (en) | 2018-01-11 | 2019-07-18 | Innovative Cellular Therapeutics Inc. | Modified cell expansion and uses thereof |
EP3873606A4 (en) * | 2018-10-30 | 2022-10-26 | MacroGenics, Inc. | CD123 X CD3 BISPECIFIC DIABODY FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANTS |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CN111718957A (zh) * | 2019-03-22 | 2020-09-29 | 南京安锐生物科技有限公司 | 一种嵌合抗原受体重组腺相关病毒颗粒及其应用 |
KR20220004042A (ko) * | 2019-05-01 | 2022-01-11 | 유니버시다데 데 산티아고 데 콤포스텔라 | 나노캡슐로 제형화된 항-kras 항체의 세포내 전달 |
WO2021045728A1 (en) * | 2019-09-03 | 2021-03-11 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
CN115212308B (zh) * | 2021-04-15 | 2023-10-20 | 中国医学科学院基础医学研究所 | Gasdermin e通路的靶向剂在治疗胰腺癌中的应用 |
WO2023278391A1 (en) * | 2021-06-29 | 2023-01-05 | Board Of Regents, The University Of Texas System | Antibodies specific to nell2 and methods of use |
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3223885A1 (de) | 1982-06-26 | 1983-12-29 | Basf Ag, 6700 Ludwigshafen | Makroporoese, hydrophile traeger fuer enzyme |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5088499A (en) | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
GB9007408D0 (en) | 1990-04-02 | 1990-05-30 | Nycomed As | Compositions |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5147631A (en) | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5234933A (en) | 1991-10-31 | 1993-08-10 | Board Of Governors Of Wayne State University And Vanderbilt University | Cyclic hydroxamic acids |
DE4210332C1 (es) | 1992-03-30 | 1993-07-15 | Gruenenthal Gmbh, 5100 Aachen, De | |
US5238832A (en) | 1992-06-08 | 1993-08-24 | Board Of Governors Of Wayne State University | Aryl aliphatic acids |
KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
DE69425464T2 (de) | 1993-02-26 | 2001-05-23 | Drug Delivery System Inst Ltd | Polysaccharidderivat und wirkstoffträger |
JP3191489B2 (ja) | 1993-05-27 | 2001-07-23 | 三菱化学株式会社 | ハロゲン化無水フタル酸の製造法 |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
MX9504664A (es) | 1994-03-07 | 1997-05-31 | Dow Chemical Co | Conjugados de dendrimeros bioactivos y/o dirigidos. |
US5786387A (en) | 1994-03-23 | 1998-07-28 | Meiji Seika Kabushiki Kaisha | Lipid double-chain derivative containing polyoxyethylene |
ZA955642B (en) | 1994-07-07 | 1997-05-06 | Ortho Pharma Corp | Lyophilized imaging agent formulation |
JP3699141B2 (ja) | 1994-09-24 | 2005-09-28 | 伸彦 由井 | 超分子構造の生体内分解性医薬高分子集合体及びその調製方法 |
US5490840A (en) | 1994-09-26 | 1996-02-13 | General Electric Company | Targeted thermal release of drug-polymer conjugates |
DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5707605A (en) | 1995-06-02 | 1998-01-13 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6127339A (en) | 1995-06-21 | 2000-10-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Peptide for binding thereto a low density lipoprotein |
US6106866A (en) | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
CA2230228C (en) | 1995-08-24 | 2006-11-14 | Purdue Research Foundation | Fluorescence lifetime-based imaging and spectroscopy in tissues and other random media |
US7241568B2 (en) * | 1996-04-03 | 2007-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anti-fibroblast growth factor-8 monoclonal antibody |
IL126659A (en) | 1996-04-19 | 2003-05-29 | Dow Global Technologies Inc | Fluorescent chelates as visual tissue specific imaging agents |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
US6080384A (en) | 1997-03-25 | 2000-06-27 | American Biogenetic Sciences, Inc. | Methods for radionuclide-labeling of biomolecules and kits utilizing the same |
US6245318B1 (en) | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
US6193659B1 (en) | 1997-07-15 | 2001-02-27 | Acuson Corporation | Medical ultrasonic diagnostic imaging method and apparatus |
US6083486A (en) | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
US6167297A (en) | 1999-05-05 | 2000-12-26 | Benaron; David A. | Detecting, localizing, and targeting internal sites in vivo using optical contrast agents |
US6254852B1 (en) | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
US7183388B2 (en) * | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
US7105171B2 (en) * | 2002-03-07 | 2006-09-12 | The Regents Of The University Of California | Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia |
WO2003106495A2 (en) * | 2002-06-14 | 2003-12-24 | Immunomedics, Inc. | MONOCLONAL ANTIBODY hPAM4 |
DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
JP2007525195A (ja) * | 2003-06-02 | 2007-09-06 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ヒト慢性リンパ球性白血病に関連する細胞表面タンパク質 |
US9012369B2 (en) * | 2004-07-06 | 2015-04-21 | Pfizer Inc. | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
MX2007011407A (es) * | 2005-03-25 | 2007-11-13 | Glycart Biotechnology Ag | Moleculas de union a antigeno dirigidas a proteoglicano de condroitinsulfato de melanoma y con aumento de afinidad de union al receptor fc y de funcion efectora. |
CA2957144C (en) | 2005-04-08 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
LT5414B (lt) * | 2005-04-13 | 2007-04-25 | Biotechnologijos Institutas | Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu |
BRPI0621065A2 (pt) * | 2005-12-16 | 2011-11-29 | Genentech Inc | anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l |
WO2008040362A2 (en) | 2006-10-04 | 2008-04-10 | Københavns Universitet | Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
WO2008070171A2 (en) | 2006-12-06 | 2008-06-12 | Minerva Biotechnologies Corp. | Method for identifying and manipulating cells |
EP2199390B1 (en) | 2007-08-30 | 2016-12-21 | Daiichi Sankyo Company, Limited | Anti-epha2 antibody |
EP2337801A4 (en) | 2008-10-06 | 2012-07-25 | Minerva Biotechnologies Corp | MUC1 ANTIBODIES * |
CA2741798A1 (en) * | 2008-10-28 | 2010-05-06 | Shionogi & Co., Ltd. | Anti-muc1 antibody |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
EP2414396B1 (en) | 2009-03-30 | 2015-02-25 | Edimer Biotech S.a. | Preparation of isolated agonist anti-edar monoclonal antibodies |
EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
FR2962450B1 (fr) | 2010-07-07 | 2014-10-31 | Commissariat Energie Atomique | Procede de preparation d'un materiau composite, materiau ainsi obtenu et ses utilisations |
-
2010
- 2010-10-08 US US12/924,952 patent/US8518405B2/en active Active
-
2011
- 2011-05-25 ES ES11831066T patent/ES2927050T3/es active Active
- 2011-05-25 EP EP11831066.3A patent/EP2624866B1/en active Active
- 2011-05-25 AU AU2011312830A patent/AU2011312830B2/en active Active
- 2011-05-25 CA CA2813814A patent/CA2813814C/en active Active
- 2011-05-25 DK DK11831066.3T patent/DK2624866T3/da active
- 2011-05-25 JP JP2013532795A patent/JP5886299B2/ja active Active
- 2011-05-25 KR KR1020137011650A patent/KR101883280B1/ko active IP Right Grant
- 2011-05-25 US US13/877,582 patent/US9090698B2/en active Active
- 2011-05-25 WO PCT/US2011/037972 patent/WO2012047317A2/en active Application Filing
- 2011-05-25 RU RU2013120483/10A patent/RU2595403C2/ru active
- 2011-05-25 MX MX2013003825A patent/MX346973B/es active IP Right Grant
- 2011-05-25 CN CN201180059040.8A patent/CN103492417B/zh active Active
- 2011-05-25 BR BR112013008480A patent/BR112013008480A2/pt not_active Application Discontinuation
-
2013
- 2013-04-03 IL IL225545A patent/IL225545A0/en unknown
- 2013-07-23 US US13/948,580 patent/US20140010759A1/en not_active Abandoned
-
2015
- 2015-07-27 US US14/810,209 patent/US20150368356A1/en not_active Abandoned
- 2015-11-25 JP JP2015229461A patent/JP6050466B2/ja active Active
-
2016
- 2016-05-13 US US15/154,596 patent/US20160319031A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9090698B2 (en) | 2015-07-28 |
IL225545A0 (en) | 2013-06-27 |
RU2595403C2 (ru) | 2016-08-27 |
AU2011312830B2 (en) | 2016-03-24 |
AU2011312830A1 (en) | 2013-05-02 |
CA2813814A1 (en) | 2012-04-12 |
US20110123442A1 (en) | 2011-05-26 |
MX2013003825A (es) | 2013-09-02 |
BR112013008480A2 (pt) | 2016-08-09 |
DK2624866T3 (da) | 2022-09-05 |
JP6050466B2 (ja) | 2016-12-21 |
RU2013120483A (ru) | 2014-11-20 |
ES2927050T3 (es) | 2022-11-02 |
US20150368356A1 (en) | 2015-12-24 |
EP2624866A4 (en) | 2014-03-05 |
WO2012047317A2 (en) | 2012-04-12 |
JP5886299B2 (ja) | 2016-03-16 |
US20130336886A1 (en) | 2013-12-19 |
US20140010759A1 (en) | 2014-01-09 |
US20160319031A1 (en) | 2016-11-03 |
JP2016053581A (ja) | 2016-04-14 |
EP2624866B1 (en) | 2022-07-06 |
US8518405B2 (en) | 2013-08-27 |
KR20140009172A (ko) | 2014-01-22 |
WO2012047317A3 (en) | 2012-05-31 |
CA2813814C (en) | 2023-04-11 |
CN103492417A (zh) | 2014-01-01 |
CN103492417B (zh) | 2016-09-28 |
EP2624866A2 (en) | 2013-08-14 |
JP2013544503A (ja) | 2013-12-19 |
KR101883280B1 (ko) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX346973B (es) | Anticuerpos especificos de tumores y usos para los mismos. | |
MX349662B (es) | Anticuerpos de antigenos antitumorales y metodos de uso. | |
MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
WO2011103016A3 (en) | Compositions and methods for inhibiting ezh2 | |
MX2013004761A (es) | Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas. | |
MX2013002535A (es) | Nuevas proteinas de union a antigenos. | |
WO2012097313A3 (en) | Therapeutic antibodies against ror-1 protein and methods for use of same | |
MX2011010955A (es) | Terapia complementaria contra el cancer. | |
WO2010030365A3 (en) | Thyroid tumors identified | |
WO2012068383A3 (en) | ncRNA AND USES THEREOF | |
EP2504363A4 (en) | ANTICLUSTERIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND THEIR USE FOR REDUCING TUMOR VOLUME | |
TN2011000524A1 (en) | Antibodies specific to cadherin -17 | |
WO2012006634A3 (en) | Prostate specific antigen (psa) peptide therapy | |
MX2011009220A (es) | Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1. | |
EP2582727A4 (en) | ANTIBODIES AGAINST ENDOPLASMINE AND THEIR USE | |
NZ704718A (en) | Epcam aptamer for detection of cancer stem cells | |
EP2519542A4 (en) | ANTI-CDH3 ANTIBODY AND ITS USE | |
WO2011112845A3 (en) | Methods and compositions related to a multi-methylation assay to predict patient outcome | |
WO2012154567A3 (en) | Human invasion signature for prognosis of metastatic risk | |
CR20120429A (es) | Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello | |
WO2012054084A3 (en) | Antibodies | |
MX336761B (es) | Compuestos para el tratamiento de cancer. | |
NZ607472A (en) | Treatment for neoplastic diseases | |
MX350807B (es) | Composiciones y metodos para el analisis de cancer de prostata. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |